Analysis of Patients with Moderate to Severe Psoriasis before Starting Biologic Therapy in the Czech Republic - Data from BIOREP Registry 2005 - 2016
Abstract
Background and objective: Evaluation of patients with severe psoriasis treated with biologics in the Czech Republic and included in the register of biological therapy BIOREP. Methods: We performed a retrospective evaluation of patients with severe psoriasis enrolled in the registry BIOREP from May 2005 to May 2016.
The number of patients on biological therapy was evaluated and analysed according to the age and gender in this period, the incidence of associated disorders was assessed and the characteristics were compared with published data in literature. Results: Baseline data were collected from 17 dermatology biological therapy centres.
As of May 2016, 1525 patients were registered in BIOREP registry with a predominance of males (63.5%). The average patient age was 50.9 years.
The mean baseline Psoriasis Area and Severity Index was 19.5 and the Dermatology Life Quality Index was 17.0. A total of 40.2% of patients reported a history of psoriatic arthritis.
In our cohort a high proportion of patients (59.2%) with cardiovascular risk factors [hypertension (36.9%), hyperlipidemia (28.6%), diabetes mellitus (12.4%), coronary heart disease (4.9%), and obesity (32.4%)] were observed. 72% of patients were overweight or obese. Only 32.1% of patients had no concomitant disease, 31.0% of patients had one, 18.4% two, 12.8% three, and 5.7% of patients four or more comorbidities.
The majority of patients had been previously treated with phototherapy (86.0%), acitretin (75.5%), methotrexate (69.3%) or ciclosporin (54.0%). Conclusion: BIOREP is the first registry of patients with psoriasis treated with biologics in Central and Eastern Europe.
Our results found a similar or even higher prevalence of comorbidities, long disease duration before biological treatment introduction and high impact on the quality of life among patients included in European registries.